A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

Pfizer

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Drug: Salmeterol; Drug: PF-610,355

Study type: Interventional

Funder types: Industry

Identifiers

NCT00468975

A7881004

Details and patient eligibility

About

A study to determine the ability of different doses of PF-610,355 to open the airways in asthmatic patients by comparison with placebo and a marketed drug that also opens the airways in asthmatic patients.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Reversible asthmatic patients (>15% increase in FEV1 following 200ug salbutamol).
• FEV1 greater than or equal to 60% predicted
• Stable disease for at least the previous 3 months

Exclusion criteria

• Subjects requiring rescue medication on greater than 2 occasions in the 72 hours prior to screening
• Subjects with a history of pulmonary disease other than asthma.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind